PTLA News and Press, Portola Pharmaceuticals Inc. From 10/25/18

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Cable One, Inc. (NYSE:CAB...

–  Relypsa president and former Exelixis chief commercial officer  brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful therapies, Avastin and Rituxan, during his tenure...

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement (PAS) filing for the large-scale Ge...

Portola Pharmaceuticals (NASDAQ: PTLA ) announces that Tao Fu, Chief Commercial Officer, has resigned effective September 21 to pursue opportunities outside the Company. A search for a successor is underway. More news on: Portola Pharmaceuticals, Healthcare stocks news, Read mor...

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September 21, 2018 to pursue opportunities outside the Company. The Company has engaged a lead...

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of Directors approved, effective as of August 31, 2018, the grant of an inducement stock optio...